Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viemed Healthcare (VMD) Cash & Equivalents (2018 - 2025)

Viemed Healthcare's Cash & Equivalents history spans 8 years, with the latest figure at $13.5 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 23.03% year-over-year to $13.5 million; the TTM value through Dec 2025 reached $13.5 million, down 23.03%, while the annual FY2025 figure was $13.5 million, 23.03% down from the prior year.
  • Cash & Equivalents reached $13.5 million in Q4 2025 per VMD's latest filing, up from $11.1 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $31.2 million in Q2 2021 to a low of $7.3 million in Q1 2024.
  • Average Cash & Equivalents over 5 years is $18.2 million, with a median of $17.2 million recorded in 2022.
  • Peak YoY movement for Cash & Equivalents: soared 269.81% in 2021, then tumbled 68.96% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $28.4 million in 2021, then plummeted by 40.46% to $16.9 million in 2022, then decreased by 24.09% to $12.8 million in 2023, then skyrocketed by 36.62% to $17.5 million in 2024, then fell by 23.03% to $13.5 million in 2025.
  • Per Business Quant, the three most recent readings for VMD's Cash & Equivalents are $13.5 million (Q4 2025), $11.1 million (Q3 2025), and $20.0 million (Q2 2025).